Benralizumab + Placebo to Benralizumab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-cystic Fibrosis Bronchiectasis
Conditions
Non-cystic Fibrosis Bronchiectasis
Trial Timeline
Jul 21, 2021 → Apr 16, 2024
NCT ID
NCT05006573About Benralizumab + Placebo to Benralizumab
Benralizumab + Placebo to Benralizumab is a phase 3 stage product being developed by AstraZeneca for Non-cystic Fibrosis Bronchiectasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05006573. Target conditions include Non-cystic Fibrosis Bronchiectasis.
What happened to similar drugs?
0 of 2 similar drugs in Non-cystic Fibrosis Bronchiectasis were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05006573 | Phase 3 | Terminated |
Competing Products
8 competing products in Non-cystic Fibrosis Bronchiectasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TIP + TIP and placebo + Placebo | Novartis | Phase 2 | 35 |
| CSL787 + Placebo | CSL | Phase 2 | 42 |
| HSK31858, tablet + Placebo | Haisco Pharmaceutical Group | Phase 3 | 47 |
| HSK31858 + placebo | Haisco Pharmaceutical Group | Phase 2 | 35 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 2 | 32 |
| Brensocatib | Insmed | Pre-clinical | 23 |
| Brensocatib 10 mg + Brensocatib 25 mg + Placebo | Insmed | Phase 3 | 37 |
| AP-PA02 | Armata Pharmaceuticals | Phase 2 | 25 |